Robert Latta (R-OH)
To amend the Federal Food, Drug, and Cosmetic Act to provide for expedited approval of priority nonprescription drugs, and for other purposes.
A Republican bill with 1 Democratic cosponsor · See the cosponsor
Last activity — Referred to the House Committee on Energy and Commerce.
In committee
Introduced and handed to a committee in the chamber it started in.
The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.
Its path through Congress
- Introduced
- In Committee
What this bill would do
This bill seeks to amend the Federal Food, Drug, and Cosmetic Act to create a pathway for the expedited approval of priority nonprescription drugs. Under this proposal, the Secretary can designate certain drugs as "priority" if they meet specific criteria, such as being a new molecular entity or providing a novel nonprescription indication. Once designated, the Secretary will take various actions to facilitate and speed up the development and review process of these drugs. The bill also requires the establishment of a list of conditions that could benefit from these drugs. Finally, the authority granted by this bill is set to expire on September 30, 2032.
Yes· 3 of 7
- Scored +5
Does this make health care easier to get in general?
The bill expedites the availability of new nonprescription drugs for various conditions, potentially increasing easier access to treatments.
- Scored +3
Does this make it easier to run a small business?
The bill provides a streamlined regulatory pathway that can benefit drug sponsors developing new nonprescription treatments.
- Scored +3
Does this make what the government does easier for the public to see?
The bill requires the Secretary to publish a list of conditions and submit a report to Congress regarding the program's implementation.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Faster Access to New Drugs: The bill allows the Secretary to take actions to "expedite the review of, an application or supplement to an application for such drug," which could lead to faster availability of new treatments (Section 506M(e)).
-
Meaningful Public Health Benefits: Priority designation can be granted to drugs intended for a "novel nonprescription indication that could provide a meaningful public health benefit" (Section 506M(d)(1)(A)).
-
Efficient Development Programs: The Secretary is directed to provide advice and communication to ensure development programs for gathering data are "as efficient as practicable" (Section 506M(e)(2)).
-
Streamlined Clinical Trials: The bill encourages making the design of nonclinical or clinical trials as efficient as possible, including the use of "real world evidence" (Section 506M(e)(5)).
Potential Negative Impacts for People
- Exclusion of Certain Drugs: Drugs that require a "risk evaluation and mitigation strategy" or are "controlled substance[s]" are not eligible for this expedited priority designation (Section 506M(d)(2)).
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Tap or hover a score for the reason it gave.
- Healthcare
- Does this make health care easier to get in general? — The bill expedites the availability of new nonprescription drugs for various conditions, potentially increasing easier access to treatments. Does this put more money into medical research? — The bill encourages more efficient development programs for gathering clinical and nonclinical data.
- Demographic And Interest Groups
- Would households on low incomes be better off under this? — Easier access to nonprescription medications may provide more affordable healthcare alternatives for low-income households. Would people in cities be better off under this? — Increased availability of nonprescription drugs may benefit urban populations with easy access to pharmacies.
- Economy And Finance
- Does this make it easier to run a small business? — The bill provides a streamlined regulatory pathway that can benefit drug sponsors developing new nonprescription treatments.
- Governance And Ideology
- Does this make what the government does easier for the public to see? — The bill requires the Secretary to publish a list of conditions and submit a report to Congress regarding the program's implementation.
- Education And Technology
- Does this put more money into scientific research? — The bill facilitates more efficient clinical trial designs and the use of real-world evidence in drug development.
- 7/20/2026
- Referred to the House Committee on Energy and Commerce.
- 1 Cosponsor added.
- Introduced in House
Greg LandsmanDemocrat · Ohio